What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
The Centers for Disease Control and Prevention (CDC) is planning a large study into potential connections...
Australia's most prolific blood and plasma donor, James Harrison, has died at age 88. Known as...
A bill that would have required women seeking medication abortions to get ultrasounds has been vetoed...
The Philadelphia school district will reportedly ignore a rule directing schools to ban transgender athletes from...
